HomeClinical TopicsFDA approves antiplatelet drug for use during PCI

FDA approves antiplatelet drug for use during PCI

On June 22, the U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor), an I.V. antiplatelet drug, for use in adults undergoing undergoing percutaneous coronary intervention (PCI). Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

covid-19 virus illustration

Will Omicron Be More Contagious Than Delta?

If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...